← All trials
NCT04767633
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2021
- Primary completion
- Apr 16, 2022
- Completion date
- Jul 16, 2022
- First posted
- Feb 23, 2021
- Last posted
- Feb 23, 2021
- Enrollment
- 590
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Azienda Ospedaliera Sant'Andrea, RomaLead sponsor
- ASO SS Antonio e Biagio e C Arrigo Alessandria, ItalyOverall official - principal investigator
- ASO SS Antonio e Biagio e C Arrigo Alessandria, ItalyReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.